Lipocine Inc (LPCN)

1.18 +0.05  +4.42% NASDAQ Oct 18, 16:00 1.21 +0.03  +2.54% Pre-Market: 08:14 USD
View Full Chart
Price Chart
View All LPCN News

News

View All Events

Events

Date Type Description
11/10/2021 Earnings Results Q3 2021 Earnings Results
08/05/2021 Earnings Results Q2 2021 Earnings Results
06/09/2021 12:00 EST AGM 2020 Annual General Meeting
05/06/2021 Earnings Results Q1 2021 Earnings Results
03/11/2021 Earnings Results Q4 2020 Earnings Results
11/10/2020 Earnings Results Q3 2020 Earnings Results
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO, is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148 and LPCN 1107.
  • URL: http://www.lipocine.com
  • Investor Relations URL: http://ir.lipocine.com/index.cfm
  • HQ State/Province: Utah
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Blend
  • Next Earnings Release: Nov. 10, 2021
  • Last Earnings Release: Aug. 05, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.